Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway

Food and Chemical Toxicology

Volumn 56, Issue , 2013, Pages 436-442

  Guo, Chao ^a   Xu, Lingyuan ^b   He, Qiaoling ^a   Liang, Tao ^a   Duan, Xiaoqun ^c   Li, Rong ^c  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF YOUJIANG MEDICAL UNIVERSITY FOR NATIONALITIES   (China)

^c GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic fibrosis; Metabolism; PI3K Akt pathway; PPAR ; Puerarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; COLCHICINE; COLLAGEN TYPE 1; GELATINASE A; HYDROXYPROLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN; PROCOLLAGEN TYPE 3; PROTEIN KINASE B; PUERARIN; SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFIBROTIC EFFECT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CARBON TETRACHLORIDE; COLLAGEN TYPE I; COLLAGEN TYPE III; DOWN-REGULATION; EXTRACELLULAR MATRIX; HEPATOCYTES; HYDROXYPROLINE; ISOFLAVONES; LIVER; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 2; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; PUERARIA; RATS; RATS, WISTAR; SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; UP-REGULATION; VASODILATOR AGENTS;

PUERARIA MONTANA VAR. LOBATA; RATTUS;

EID: 84875768328     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.02.051     Document Type: Article

References (49)

1. Akimov S.S., Belkin A.M. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci. 2001, 114:2989-3000.
2. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:245-249.
3. Calligaris S.D., Bellarosa C., Giraudi P., Wennberg R.P., Ostrow J.D., Tiribelli C. Cytotoxicity is predicted by unbound and not total bilirubin concentration. Pediatr. Res. 2007, 62:576-580.
4. Cartón J.A., Collazos J., de la Fuente B., García-Alcalde M.L., Suarez-Zarracina T., Rodríguez-Guardado A., Asensi V. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antiviral Ther. 2011, 16:27-35.
5. Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract. Res. Clin. Gastroenterol. 2011, 25:291-303.
6. Chen R., Xue J., Xie M. Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-β1 expression. J. Nutr. Biochem. 2012, 23:1080-1085.
7. Choi G., Runyon B.A. Alcoholic hepatitis: a clinician's guide. Clin. Liver Dis. 2012, 16:371-385.
8. Chung M.J., Sung N.J., Park C.S., Kweon D.K., Mantovani A., Moon T.W., Lee S.J., Park K.H. Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur. J. Pharmacol. 2008, 578:159-170.
9. Collazos J., Cartón J.A., Asensi V. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus. Curr. HIV Res. 2011, 9:339-345.
10. Cong M., Iwaisako K., Jiang C., Kisseleva T. Cell signals influencing hepatic fibrosis. Int. J. Hepatol. 2012, 8:1-18.
11. Carpino G., Morini S., Ginanni Corradini S., Franchitto A., Merli M., Siciliano M., Gentili F., Onetti Muda A., Berloco P., Rossi M., Attili A.F., Gaudio E. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig. Liver Dis. 2005, 37:349-356.
12. Feng Y., Cheung K.F., Wang N., Liu P., Nagamatsu T., Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chin. Med. 2009, 4:16-27.
13. Giannini E.G., Testa R., Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005, 172:367-379.
14. Gong Y. Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine. Chin. J. Integr. Med. 2012, 18:245-249.
15. Hu Y.B., Li D.G., Lu H.M. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 2007, 9:217-229.
16. Huang J.F., Chuang Y.H., Dai C.Y., Yu M.L., Huang C.F., Hsiao P.J., Hsieh M.Y., Huang C.I., Yeh M.L., Yang J.F., Lin Z.Y., Chen S.C., Chuang W.L. Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection. Hepatol. Res. 2011, 41:430-436.
17. Hwang Y.P., Choi C.Y., Chung Y.C., Jeon S.S., Jeong H.G. Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. Arch. Pharm. Res. 2007, 30:1309-1317.
18. Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:195-206.
19. Li C., Luo J., Li L., Cheng M., Huang N., Liu J., Waalkes M.P. The collagenolytic effects of the traditional Chinese medicine preparation, Han-Dan-Gan-Le, contribute to reversal of chemical-induced liver fibrosis in rats. Life Sci. 2003, 72:1563-1571.
20. Li R., Xu L., Liang T., Li Y., Zhang S., Duan X. Puerarin mediates hepatoprotection against CCl(4)-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. Food Chem. Toxicol. 2013, 52:69-75.
21. Limdi J.K., Hyde G.M. Evaluation of abnormal liver function tests. Postgrad. Med. J. 2003, 79:307-312.
22. Liu J., Tan H., Sun Y., Zhou S., Cao J., Wang F. The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol. Cell Biochem. 2009, 327:219-228.
23. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
24. Mao Y., Schwarzbauer J.E. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol. 2005, 24:389-399.
25. Mormone E., Lu Y., Ge X., Fiel M.I., Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. Gastroenterology 2012, 142:612-621.
26. Nikolaidis N., Kountouras J., Giouleme O., Tzarou V., Chatzizisi O., Patsiaoura K., Papageorgiou A., Leontsini M., Eugenidis N., Zamboulis C. Colchicine treatment of liver fibrosis. Hepatogastroenterology 2006, 53:281-285.
27. Noh B.K., Lee J.K., Jun H.J., Lee J.H., Jia Y., Hoang M.H., Kim J.W., Park K.H., Lee S.J. Restoration of autophagy by puerarin in ethanol-treated hepatocytes via the activation of AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 2011, 414:361-366.
28. Schultze S.M., Hemmings B.A., Niessen M. Tschopp O.PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev. Mol. Med. 2012, 14:124-132.
29. Sun K., Wang Q., Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol. Sin. 2006, 27:715-723.
30. Tacke F., Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev. Gastroenterol. Hepatol. 2012, 6:67-80.
31. Talwalkar J.A. Antifibrotic therapies-emerging biomarkers as treatment end points. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:59-61.
32. Troeger J.S., Mederacke I., Gwak G.Y., Dapito D.H., Mu X., Hsu C.C., Pradere J.P., Friedman R.A., Schwabe R.F. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012, 143:1073-1083.
33. Tsukamoto H., She H., Hazra S., Cheng J., Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J. Gastroenterol. Hepatol. 2006, 21:102-105.
34. Wang B.E. Treatment of chronic liver diseases with traditional Chinese medicine. J. Gastroenterol. Hepatol. 2000, 15:67-70.
35. Wang Y., Jiang X.Y., Liu L., Jiang H.Q. Phosphatidylinositol 3-kinase/Akt pathway regulates hepatic stellate cell apoptosis. World J. Gastroenterol. 2008, 14:5186-5191.
36. Wang Z., Xu J.P., Zheng Y.C., Chen W., Sun Y.W., Wu Z.Y., Luo M. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatobiliary Pancreat. Dis. Int. 2011, 10:64-71.
37. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003, 33:105-136.
38. Wisse E., Braet F., Luo D., De Zanger R., Jans D., Crabbé E., Vermoesen A. Structure and function of sinusoidal lining cells in the liver. Toxicol. Pathol. 1996, 24:100-111.
39. Wong K.H., Li G.Q., Li K.M., Razmovski-Naumovski V., Chan K. Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J. Ethnopharmacol. 2011, 134:584-607.
40. Xing G., Dong M., Li X., Zou Y., Fan L., Wang X., Cai D., Li C., Zhou L., Liu J., Niu Y. Neuroprotective effects of puerarin against beta-amyloid-induced neurotoxicity in PC12 cells via a PI3K-dependent signaling pathway. Brain Res. Bull. 2011, 85:212-218.
41. Yang C., Zeisberg M., Mosterman B., Sudhakar A., Yerramalla U., Holthaus K., Xu L., Eng F., Afdhal N., Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003, 124:147-159.
42. Yang L., Chan C.C., Kwon O.S., Liu S., McGhee J., Stimpson S.A., Chen L.Z., Harrington W.W., Symonds W.T., Rockey D.C. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:902-911.
43. Yang L., Stimpson S.A., Chen L., Wallace Harrington W., Rockey D.C. Effectiveness of the PPARγ agonist, GW570, in liver fibrosis. Inflamm. Res. 2010, 59:1061-1071.
44. Yang M.D., Chiang Y.M., Higashiyama R., Asahina K., Mann D.A., Mann J., Wang C.C., Tsukamoto H. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor γ in hepatic stellate cells for their antifibrotic effect. Hepatology 2012, 55:1271-1281.
45. Zhang S., Ji G., Liu J. Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J. Nutr. Biochem. 2006, 17:485-491.
46. Zhang Z., Li S., Jiang J., Yu P., Liang J., Wang Y. Preventive effects of Flos Perariae (Gehua) water extract and its active ingredient puerarin in rodent alcoholism models. Chin. Med. 2010, 5:36-42.
47. Zhang F., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal. 2012, 24:596-605.
48. Zhou Y.X., Chen J., Li J.P., Wang Y.L., Jin X.D. Chinese medicinal herbs in treating model rats with hepatic fibrosis. Afr. J. Tradit. Complement Altern. Med. 2009, 7:104-108.
49. Zois C.D., Baltayiannis G.H., Karayiannis P., Tsianos E.V. Systematic review: hepatic fibrosis - regression with therapy. Aliment Pharmacol. Ther. 2008, 28:1175-1187.